Deep compartment models
CPT Pharmacometrics Syst Pharmacol. 2022;11:934–945
Replacement therapy in haemophilia A
Haemophilia. 2022;1–9.
Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)
TH Open 2022 Feb 3;6(1):e60-e69. doi: 10.1055/a-1760-0105. eCollection 2022 Jan.
Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice
Blood Advances 2021 Oct 26;5(20):4314-4325. doi: 10.1182/bloodadvances.2021005096.
Patient-reported outcomes in autosomal inherited bleeding disorders
Haemophilia. 2022;28:197–214
Persoonlijke Gezondheidsomgeving voor meer inzicht en regie
NVHP Faktor editie maart 2022 De volledige Faktor kan gelezen worden op de NVHP website
Hoe beïnvloedt de bloedvatwand de bloedstolling?
NVHP Faktor editie maart 2022 De volledige Faktor kan gelezen worden op de NVHP website
Trombocytopathie in Nederland
NVHP Faktor editie maart 2022 De volledige Faktor kan gelezen worden op de NVHP website
Validation meeting
On February 9th, WP09 (ethics of gene transfer for haemophilia) conducted a validation meeting. WP09 is currently working on a qualitative interview study in which they collect stakeholders’ morally reasoned opinions on gene transfer for haemophilia. During the validation meeting, the preliminary results were presented to experts from the field, [...]
Emicizumab Dosing in Children and Adults with Hemophilia A
Thromb Haemost 2022;122:208–215